ZTA Biotech

ZTA Biotech is the Intellectual Rights holder of the protocol and is represented by a Hungarian scientist. The formula was developed by an international team of researchers including a Canadian, an Israeli, and a Dutch scholar. The main research direction is achieved by an in-house developed, highly specialized software package for simulation and modeling of critical protein-protein interactions. The results based on the prediction of the algorithm are analyzed and translated into commercial products.

Content by ZTA Biotech

Biotech Team Develops ELISA Protocol for COVID-19 IgG Antibody Detection
| 2 min read
Page 1 of 1 - 1 Total Items

CURRENT ISSUE - March/2026

When the Unexpected Hits

How Lab Leaders Can Prepare for Safety Crises That Don’t Follow the Script

Lab Manager March 2026 Cover Image